open access

Vol 5, No 1 (2001)
Prace oryginalne
Published online: 2001-01-12
Get Citation

3. Losartan and Enalapril in the Treatment of Essentail Hypertension — Effect on LeftVentricular Mass and Function

Aleksander Goch, Zenon Gawor, Grażyna Dąbrowska, Jan Henryk Goch
Nadciśnienie tętnicze 2001;5(1):21-28.

open access

Vol 5, No 1 (2001)
Prace oryginalne
Published online: 2001-01-12

Abstract

Background: The aim of the study was to assess the effect of losartan and enalapril on arterial blood pressure and left ventricular mass and selected parameters of its function in patients with hypertension.

Material and methods Examinations were performed in 61 subjects (43 men and 18 women) aged 37–70 years (mean 56,8 ± 8). Losartan was applied in 31 subjects in a dose 50 mg/24 h, while enalapril in 30 subjects in a dose 10–20 mg/24 h for 12 months. 17 subjects on losartan and 18 on enalapril had left ventricular hypertrophy. Arterial pressure measurements and echocardiography were performed before and after 1, 3, 9 and 12 months of treatment.

Results: In the initial period of the therapy greater hypotensive effect was observed in the group of patients without ventricular hypertrophy; after 3 months losartan and enalapril hypotensive effect was similar in subjects with and without ventricular hypertrophy. Left ventricular mass index decreased, ejection fraction increased after 3–6 months of losartan and enalapril therapy, while early to atrial peak flow velocity ratio (E/A) increased after 1–3 months of the therapy. Analysis of the changes of echocardiographic parameters values showed that left ventricular mass index decreased only in the group of patients with left ventricular hypertrophy.

Conclusion: Losartan and enalapril demonstrate similar hypotensive effect and similar effect on left ventricular mass and function in subjects with essential hypertension.

Abstract

Background: The aim of the study was to assess the effect of losartan and enalapril on arterial blood pressure and left ventricular mass and selected parameters of its function in patients with hypertension.

Material and methods Examinations were performed in 61 subjects (43 men and 18 women) aged 37–70 years (mean 56,8 ± 8). Losartan was applied in 31 subjects in a dose 50 mg/24 h, while enalapril in 30 subjects in a dose 10–20 mg/24 h for 12 months. 17 subjects on losartan and 18 on enalapril had left ventricular hypertrophy. Arterial pressure measurements and echocardiography were performed before and after 1, 3, 9 and 12 months of treatment.

Results: In the initial period of the therapy greater hypotensive effect was observed in the group of patients without ventricular hypertrophy; after 3 months losartan and enalapril hypotensive effect was similar in subjects with and without ventricular hypertrophy. Left ventricular mass index decreased, ejection fraction increased after 3–6 months of losartan and enalapril therapy, while early to atrial peak flow velocity ratio (E/A) increased after 1–3 months of the therapy. Analysis of the changes of echocardiographic parameters values showed that left ventricular mass index decreased only in the group of patients with left ventricular hypertrophy.

Conclusion: Losartan and enalapril demonstrate similar hypotensive effect and similar effect on left ventricular mass and function in subjects with essential hypertension.

Get Citation

Keywords

losartan; enalapril; arterial hypertension; left ventricular hypertrophy

About this article
Title

3. Losartan and Enalapril in the Treatment of Essentail Hypertension — Effect on LeftVentricular Mass and Function

Journal

Arterial Hypertension

Issue

Vol 5, No 1 (2001)

Pages

21-28

Published online

2001-01-12

Bibliographic record

Nadciśnienie tętnicze 2001;5(1):21-28.

Keywords

losartan
enalapril
arterial hypertension
left ventricular hypertrophy

Authors

Aleksander Goch
Zenon Gawor
Grażyna Dąbrowska
Jan Henryk Goch

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl